ENA Respiratory announces research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in […]

Read more

First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials

ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity Sydney, Australia, 28 September 2021 – ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory […]

Read more

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal for most infections Company is recruiting study participants in the Sydney, Australia area Sydney, Australia, 13 July 2021 – ENA Respiratory, a biotechnology company developing a first-in-class nasal […]

Read more

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051 Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory therapy expert Ruth Tal-Singer, Ph.D., to Board of Directors Sydney, Australia, 15 June – ENA Respiratory, a biotechnology company developing a first-in-class […]

Read more

ENA Respiratory announces an extension of its Series A and positive COVID-19 ferret challenge study results

A novel nasal treatment developed to boost the natural human immune system to fight common colds and flu, has proved remarkably successful in reducing COVID-19 viral replication test results, released today, reveal. The novel product, INNA-051, being developed by Australian biotech company, Ena Respiratory, reduced viral replication by up to 96 percent in a gold-standard […]

Read more